A series of novel 1-piperidinesulfonylurea compounds derived from a pyrimidine monocarboxylic acid have been prepared by reacting an appropriate sulfamide with an organic isocyanate or a trisubstituted urea equivalent thereof. The sulfamylureas so obtained are useful in therapy as oral hypoglycemic agents. Typical members include those compounds derived from 1,3-dimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione-5-carboxylic acid, of which 1-(bicyclo[2.2.1]hept-5-en-2-yl-endo-methyl)-3-4-[2-(1,3-dimethyl-1,2,3,4 -tetrahydropyrimidine-2,4-dione-5-carboxamido)ethyl]-1-piperidinesulfonyl}u rea is a most preferred embodiment.
一系列新型的1-
哌啶磺酰
脲类化合物由
咪唑单
羧酸与适当的磺酰胺通过与有机
异氰酸酯或三取代
脲等价物反应制备而成。所得的磺酰
脲类化合物在治疗中作为口服降糖药物具有应用价值。典型的成员包括从1,3-二甲基-1,2,3,4-四氢
嘧啶-2,4-二酮-5-
羧酸衍生的化合物,其中1-(双环[2.2.1]庚-5-烯-2-基内甲基)-3-4-[2-(1,3-二甲基-1,2,3,4-四氢
嘧啶-2,4-二酮-5-羧酰胺基)乙基]-1-
哌啶磺酰}
脲是其中最优选的实施例。